Corcept Shares Rise More Than 45% in Six Months: Here's Why [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
The company's sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters. The company is also making good progress with its promising set of pipeline candidates. Factors Driving CORT Stock in the Given Time Frame Corcept has made steady progress with the development of its lead pipeline candidate, relacorilant, which is being evaluated in the phase III GRACE study for the treatment of Cushing's syndrome, also known as hypercortisolism. Image Source: Zacks Investment Research The GRACE study comprises two parts — the open-label portion and the randomized withdrawal phase. In May 2024, CORT announced that the GRACE study met the primary endpoint in the randomized withdrawal phase. Data from the same showed that patients who were treated with relacorilant experienced loss of blood pressure control, the study's primary endpoint, versus placebo
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Does Corcept Therapeutics (CORT) Have a Long Runway for Growth? [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $38.00 to $67.00. They now have an "overweight" rating on the stock.MarketBeat
- Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth [Seeking Alpha]Seeking Alpha
- Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors [Yahoo! Finance]Yahoo! Finance
- Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
CORT
Earnings
- 7/29/24 - Beat
CORT
Sec Filings
- 9/19/24 - Form 4
- 9/5/24 - Form 4
- 9/5/24 - Form 4
- CORT's page on the SEC website